NCT00943319 · OUTCOME

Overall Survival

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies · Source last updated 2019-02-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: days
Interval / dispersion: 95% Confidence Interval
Time frame: 5 years

What was measured

Overall Survival measured as median survival in days

Groups in this outcome

Busulfan and Fludarabine

Intravenous busulfan (Busulfan®) in combination with fludarabine Busulfan: Daily intravenous dosing to target AVC Fludarabine: Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose. Campath: All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times). Stem Cell Transplant: Infusion of bone marrow and donors(related/ unrelated).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Busulfan and Fludarabine	50

Reported measurements

Source class 1

Values in days · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Busulfan and Fludarabine	161	Not reported	121	305	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
121
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
305
group Ids
OG000
non Inferiority Type
OTHER
param Type
Median Survival time
param Value
161
statistical Method
Product limit survival estimate

Complete source fields

analyses

ci Lower Limit
121
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
305
group Ids
OG000
non Inferiority Type
OTHER
param Type
Median Survival time
param Value
161
statistical Method
Product limit survival estimate

classes

categories
measurements
group Id
OG000
lower Limit
121
upper Limit
305
value
161

denoms

counts
group Id
OG000
value
50
units
Participants

description

Overall Survival measured as median survival in days

dispersion Type

95% Confidence Interval

groups

description
Intravenous busulfan (Busulfan®) in combination with fludarabine Busulfan: Daily intravenous dosing to target AVC Fludarabine: Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose. Campath: All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times). Stem Cell Transplant: Infusion of bone marrow and donors(related/ unrelated).
id
OG000
title
Busulfan and Fludarabine

param Type

MEDIAN

reporting Status

POSTED

time Frame

5 years

title

Overall Survival

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice